Targeting KRASG12D Mutations: Discovery of Small Molecule Inhibitors for the Potential Treatment of Intractable Cancers

Abstract

The KRASG12D mutation, frequently found in pancreatic cancer, is representative of various challenging cancers and is a crucial target for chemotherapy drug development. Researchers are exploring highly selective and potent small molecule inhibitors of KRASG12D to meet the needs of patients with this mutation. The Patent Highlight reveals novel compounds capable of inhibiting KRASG12D proteins, potentially useful in treating KRASG12D-associated diseases, including cancers.